Showing results (201-210 of 589) with videos related to
Sort By:
Pageof 59
Journal of Translational Medicine|April 22, 2023
The "Great Debate" at Immunotherapy Bridge 2022, Naples, November 30th-December 1st, 2022Paolo A Ascierto, Renier Brentjens, Samir N Khleif, et al.AJR. American Journal of Roentgenology|June 20, 2008
Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapyAdeel Sabir, Rachel Schor-Bardach, Carol J Wilcox, et al.Nature Reviews. Clinical Oncology|February 18, 2026
Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalizationDouglas B Johnson, Amin H Nassar, Ayesha Aijaz, et al.Journal of the National Comprehensive Cancer Network : JNCCN|July 13, 2022
The Risk of Opportunistic Infections and the Role of Antibiotic Prophylaxis in Patients on Checkpoint Inhibitors Requiring SteroidsNeil J Shah, Michael R Cook, Tianmin Wu, et al.JCO Oncology Practice|July 14, 2025
Long-Term Performance of Prognostic Models for Advanced Renal Cell Carcinoma in the Era of Improved Survival With Immune Checkpoint InhibitorsCharlene M Mantia, Opeyemi A Jegede, David F McDermott, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2003
Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinomaJared A Gollob, Korina G Veenstra, Robert A Parker, et al.The Oncologist|December 28, 2022
Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3Luis Meza, David F McDermott, Bernard Escudier, et al.Molecular Cancer Therapeutics|August 12, 2010
Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signalingRupal S Bhatt, Xiaoen Wang, Liang Zhang, et al.Cancer Chemotherapy and Pharmacology|April 1, 2018
Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignanciesBoaz Mendzelevski, Georg Ferber, Filip Janku, et al.The Lancet. Oncology|August 8, 2020
Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and researchDouglas B Johnson, Kerry L Reynolds, Ryan J Sullivan, et al.Pageof 59